Free Trial
NYSE:NUVB

Nuvation Bio (NUVB) Stock Price, News & Analysis

Nuvation Bio logo
$1.96 +0.17 (+9.22%)
Closing price 06/20/2025 03:59 PM Eastern
Extended Trading
$1.98 +0.02 (+1.02%)
As of 06/20/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Nuvation Bio Stock (NYSE:NUVB)

Key Stats

Today's Range
$1.84
$2.01
50-Day Range
$1.73
$2.53
52-Week Range
$1.54
$3.97
Volume
12.71 million shs
Average Volume
2.78 million shs
Market Capitalization
$665.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.17
Consensus Rating
Buy

Company Overview

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Nuvation Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
69th Percentile Overall Score

NUVB MarketRank™: 

Nuvation Bio scored higher than 69% of companies evaluated by MarketBeat, and ranked 907th out of 2,787 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Nuvation Bio has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Nuvation Bio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Nuvation Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Nuvation Bio are expected to decrease in the coming year, from ($0.36) to ($0.64) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Nuvation Bio is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Nuvation Bio is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Nuvation Bio has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Nuvation Bio's valuation and earnings.
  • Percentage of Shares Shorted

    18.67% of the float of Nuvation Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Nuvation Bio has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Nuvation Bio has recently increased by 11.90%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Nuvation Bio does not currently pay a dividend.

  • Dividend Growth

    Nuvation Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    18.67% of the float of Nuvation Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Nuvation Bio has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Nuvation Bio has recently increased by 11.90%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Nuvation Bio has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 14 news articles for Nuvation Bio this week, compared to 4 articles on an average week.
  • Search Interest

    18 people have searched for NUVB on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added Nuvation Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Nuvation Bio insiders have bought 1,536.00% more of their company's stock than they have sold. Specifically, they have bought $818,000.00 in company stock and sold $50,000.00 in company stock.

  • Percentage Held by Insiders

    29.93% of the stock of Nuvation Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    61.67% of the stock of Nuvation Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Nuvation Bio's insider trading history.
Receive NUVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvation Bio and its competitors with MarketBeat's FREE daily newsletter.

NUVB Stock News Headlines

Founder of Nuvation Bio David Hung Buys More Stock
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
See More Headlines

NUVB Stock Analysis - Frequently Asked Questions

Nuvation Bio's stock was trading at $2.66 on January 1st, 2025. Since then, NUVB stock has decreased by 26.5% and is now trading at $1.9550.
View the best growth stocks for 2025 here
.

Nuvation Bio Inc. (NYSE:NUVB) announced its earnings results on Wednesday, May, 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.16). The business had revenue of $3.08 million for the quarter, compared to analysts' expectations of $0.42 million. Nuvation Bio had a negative net margin of 5,534.21% and a negative trailing twelve-month return on equity of 44.14%.
Read the conference call transcript
.

Nuvation Bio's top institutional shareholders include Vanguard Group Inc. (4.55%), MPM Bioimpact LLC (1.37%), Millennium Management LLC (1.11%) and Charles Schwab Investment Management Inc. (0.56%). Insiders that own company stock include David Hung, Oleg Nodelman, Xiangmin Cui, Kim D Blickenstaff, Robert Mashal and Dongfang Liu.
View institutional ownership trends
.

Shares of NUVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nuvation Bio investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
5/07/2025
Today
6/20/2025
Next Earnings (Estimated)
8/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:NUVB
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.17
High Stock Price Target
$10.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+266.6%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$567.94 million
Net Margins
-5,534.21%
Pretax Margin
-5,534.21%

Debt

Sales & Book Value

Annual Sales
$7.87 million
Price / Cash Flow
N/A
Book Value
$1.37 per share
Price / Book
1.43

Miscellaneous

Free Float
238,422,000
Market Cap
$665.21 million
Optionable
Optionable
Beta
1.37
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NYSE:NUVB) was last updated on 6/21/2025 by MarketBeat.com Staff
From Our Partners